Purpose Cytochrome b 5 (encoded by CYB5A) and NADH cytochrome b 5 reductase (encoded by CYB5R3) detoxify aromatic and heterocyclic amine mammary carcinogens found in cigarette smoke. We hypothesized that CYB5A and CYB5R3 polymorphisms would be associated with breast cancer risk in women. Methods We characterized the prevalence of 18 CYB5A and CYB5R3 variants in genomic DNA from African American (AfrAm) and Caucasian (Cauc) women from the Carolina Breast Cancer Study population (1,946 cases and 1,747 controls) and determined their associations with breast cancer risk, with effect modification by smoking. Results A CYB5R3 variant, I1M?6T (rs8190370), was significantly more common in breast cancer cases (MAF 0.0238) compared with controls (0.0169, p = 0.039); this was attributable to a higher MAF in AfrAm cases (0.0611) compared with AfrAm controls (0.0441, p = 0.046; adjusted OR 1.41, CI 0.98-2.04; p = 0.062). When smoking was considered, I1M?6T was more strongly associated with breast cancer risk in AfrAm smokers (adjusted OR 2.10, 1.08-4.07; p = 0.028) compared with never smokers (OR = 1.21; 0.77-1.88; p for interaction = 0.176). I1M?6T and three additional CYB5R3 variants, -251T, I8-1676C, and *392C, as well as two CYB5A variants, 13G and I2-992T, were significantly more common in AfrAms compared with Caucs. Conclusions CYB5R3 I1M?6C[T should be considered in future molecular epidemiologic studies of breast cancer risk in AfrAms. Further, variants in CYB5A and CYB5R3 should be considered in the evaluation of other tumors in AfrAms that are associated with aromatic and heterocyclic amine exposures, to include prostate, bladder, and colon cancers.
Introduction
Breast cancer has a high incidence in industrialized countries, and women who move from low-risk to high-risk countries acquire a breast cancer risk of the host country in as little as two generations [1, 2] . Environmental factors including diet, smoking, and pollutants appear to play an etiologic role. The aromatic amine 4-aminobiphenyl (4-ABP) is a mammary carcinogen in rodents that is found in cigarette smoke [3, 4] , and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) is another mammary carcinogen found in cigarette smoke and welldone meats [5] [6] [7] . Both 4-ABP and PhIP lead to DNA adducts that have been found in the breast tissue and milk of women [8, 9] . These adducts have also been correlated with smoking exposures [10, 11] . Further, some studies have found higher levels of DNA adducts in breast cancer patients versus controls [12, 13] , although an established relationship between these DNA adducts and breast cancer remains to be proven. Epidemiologic studies of smoking and breast cancer risk have been mixed, with some studies finding modest positive associations [14] [15] [16] [17] [18] [19] [20] , and other studies yielding no association [21] [22] [23] [24] [25] [26] [27] [28] . These inconsistent results could be due, in part, to individual differences in the disposition of tobacco carcinogens after similar smoking exposures.
Both PhIP and 4-ABP are bioactivated to arylhydroxylamine metabolites [29] [30] [31] , which ultimately form mutagenic DNA adducts (Fig. 1) . The disposition of these arylhydroxylamines appears to vary among individuals, in which exposure of individual primary human mammary epithelial cell lines to standard concentrations of PhIP hydroxylamine results in more than 75-fold variability in DNA adduct formation [32] . The hydroxylamines of PhIP and 4-ABP are reduced back to their parent compounds, which are not directly mutagenic, by cytochrome b 5 (b5) and NADH cytochrome b 5 reductase (b5R) [33] . Reduction of arylhydroxylamines by this pathway is substantially more efficient than generation of these metabolites by oxidation of the parent compound [34] , which suggests that variability in the b5/b5R pathway could modulate the amount of arylhydroxylamine available for DNA adduct formation.
We have found individual differences in cytochrome b 5 and NADH cytochrome b 5 reductase protein expression and arylhydroxylamine detoxification activities in both human liver and breast samples, with more than 75-fold variability in activities in 70 breast samples from women undergoing reduction mammoplasty or lumpectomy [35, 36] . We further found polymorphisms in the genes CYB5A and CYB5R3, which encode b5 and b5R, in tissues with outlier low protein expression and activities [35, 36] . Many of these variants were found only or predominantly in African American samples.
Based on these findings, we hypothesized that polymorphisms in CYB5A or CYB5R3 contribute to breast cancer risk, particularly in women who smoke. We further hypothesized that such polymorphisms would be more common in African American compared with Caucasian women. The purpose of this study therefore was to screen for the prevalence of 18 CYB5A and CYB5R3 variants in African American and Caucasian women with breast cancer [invasive or carcinoma in situ (CIS)], compared with age-matched unaffected controls, using the Carolina Breast Cancer Study population [37] , and to determine whether CYB5A or CYB5R3 polymorphisms were associated with breast cancer risk in relationship to smoking. [33] . Reverse reduction by the b5/b5R pathway is up to 55 times more efficient than forward oxidation by P450 0 s [34] . Hydroxylamine metabolites may also be detoxified by glutathione S-transferases (GST's) or UDPglucuronosyltransferases (UGT's), or can be further bioactivated by O-acetylation or O-sulfonation. This final bioactivation step can lead to DNA adducts via arylnitrenium ion formation
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Materials and methods
Carolina Breast Cancer Study population
The Carolina Breast Cancer Study (CBCS) is a case-control study population of women with breast cancer from 24 counties of central and eastern North Carolina [37] . Women who were diagnosed with invasive breast cancer or CIS between the ages of 20-74 were identified through the North Carolina Central Cancer Registry; population-based controls were frequency-matched to cases by age (within 5 years) and race [37] . Race was self-reported, and 144 ancestry informative markers (AIMs) were used to estimate West African genetic ancestry and control for population stratification [38] . The majority of subjects in the CBCS were Caucasian (Cauc) or African American (AfrAm) [39] , with 1.5 % of the population from Native American, Asian, Hispanic, or multiracial groups. Only Cauc and AfrAm subjects were analyzed in the present study, to include DNA samples from 1,946 breast cancer cases (742 AfrAm and 1,204 Cauc) and 1,747 controls (658 AfrAm and 1,089 Cauc). Smoking history was recorded for all subjects, to include active status, packs per day, duration, and time since cessation [27] . Characteristics of CBCS participants included in the study are listed in Table 1 .
Genotyping
Genomic DNA samples from all women were genotyped for 18 single nucleotide polymorphisms (SNPs), 8 in CYB5A (Table 2 ) and 10 in CYB5R3 (Table 3 ). SNPs were selected based on the following criteria: (1) a variant previously observed in breast or liver samples with low protein expression or arylhydroxylamine reduction activities [35, 36] ; (2) a reported non-synonymous cSNP (NCBI SNP database; www.ncbi.nlm.nih.gov/); or (3) a reported SNP in a region predicted to affect protein function, splicing, or transcription factor or miRNA binding, even if apparently rare. For the latter predictions, the possible effects of coding polymorphisms on protein function were evaluated using PMut (mmb.pcb.ub.es/PMut/), SIFT (sift.jcvi.org/) and PolyPhen-2 (genetics.bwh.harvard.edu/pph2/index.shtml) software. The effects of intronic variants on splicing were modeled with the Human Splicing Finder suite of software (HSF, MaxEnt, and ESE Finder; www.umd.be/HSF/). The influence of variants on transcription factor binding was predicted with the MATCH program (www.bioinfo.de/isb/ gcb01/poster/goessling.html) and the ENCODE database [40] (http://genome.cse.ucsc.edu/encode/), and the effects of 3 0 UTR (untranslated region) SNPs on miRNA binding were predicted with UTRscan (itbtools.ba.itb.cnr.it/utrscan).
The PCR-based Taqman Genotyping Assay (Applied Biosystems, Foster City, CA) was utilized for most polymorphisms and was performed at the University of North Carolina at Chapel Hill. SNPs that failed the Taqman assay were evaluated by pyrosequencing, using the PSQ TM 96MA System (Biotage AB, Uppsala, Sweden), at the University of Wisconsin Carbone Comprehensive Cancer Center. Both SNP screening techniques were validated by running positive and negative genomic DNA controls from liver or breast samples, where available, in which the allele of interest had been previously established by direct sequencing [35, 36] . A total of 144 ancestry informative markers (AIMs) were also genotyped to estimate African and European ancestry [41] . These AIMs were selected from a panel that has been used by others to estimate ancestry in African Americans [42, 43] .
Data analyses
Prior to association analysis, SNPs were checked for genotyping efficiency and tested for deviation from genotype proportions expected within control groups, stratified by race under Hardy-Weinberg equilibrium (HWE) conditions using chi-square testing. Minor allele frequencies (MAFs) and genotypes for each SNP were then compared between AfrAm and Cauc women in the control groups, and between women with breast cancer and controls (both across all subjects and within the two racial groups), using chi-square testing with p \ 0.05. Breast cancer risk was calculated using unconditional logistic regression (SAS software program) in order to quantify the association with CYB5A and CYB5R3 genotypes, with adjustment for age and African ancestry. An offset term was included in models to account for randomized recruitment sampling. The sample size provided 80 % power to detect odds ratios of 1.2 or greater for alleles with a frequency of 5 % or greater in the population overall. We also estimated odds ratios stratified by smoking status (ever, never). As an exploratory analysis, we modeled multiplicative interactions between genotype and smoking using a likelihood ratio test; however, power for testing interactions between genotype and smoking, stratified by race, was fairly limited.
Results
Allele detection
Five previously reported CYB5A variants, rs36082929 [35] p = 0.726)), due to very low allele frequencies. No other variant was significantly different between cases and controls, either in the population overall or as stratified by race.
Breast cancer risk was further evaluated for I1M?6C[T in relationship to smoking status ( Table 5 ). Because of relatively low numbers of carriers for most alleles, smoking status was collapsed by necessity into two separate categories, ever smokers, and never smokers (defined as less than 100 lifetime cigarettes). The CYB5R3 I1M?6T allele was significantly associated with breast cancer risk in ever smokers [OR 1.97, 95 % confidence interval (CI) 1.03-3.77], and in particular in AfrAm ever smokers (OR 2.10, 95 % CI 1.08-4.07). This relationship was not as strong among AfrAm never smokers (OR 1.21, 95 % CI 0.77-1.88; p = 0.4096). In Cauc women, allele frequencies for I1M?6T were too low to determine risk when stratified by smoking status (Table 5) . Interactions between the I1M?6 genotype and smoking for breast cancer risk were also modeled. The p value for interactions was 0.162 for all subjects and 0.176 for the AfrAm population.
In silico analysis of the 1M?6locus
In silico analyses were performed on the IM?6 polymorphic locus. The reference C allele was conserved among primates, rodents, and rabbits (UCSC Genome Browser; genome.ucsc.org). The T variant was predicted by human As for CYB5A, two variants were more prevalent in AfrAm women (Table 4 ). The intronic SNP I2-992T was found with a MAF of 0.1689 in AfrAm controls and was predicted to be within a binding site for NF-jB. The nonsynonymous cSNP 13T[G (Ser5Ala) was found only in AfrAm subjects, but with a very low frequency (MAF 0.0069).
Discussion
4-ABP and PhIP are mammary carcinogens that are found in tobacco smoke. These chemicals are bioactivated to their arylhydroxylamine metabolites, which lead to DNA adducts that are thought to initiate cancer [29] [30] [31] . Cytochrome b 5 and its reductase oppose this bioactivation step; this pathway, found in both liver and breast tissues, is a potential source of individual variability in response to these carcinogens [33, 34] . We hypothesized that variants in the CYB5A and CYB5R3 genes encoding this pathway would be associated with breast cancer risk in women who smoke. We further hypothesized that several CYB5A and CYB5R3 variants that we previously found only in African American liver and breast tissues (Table 2) would be overrepresented in AfrAm women in this larger population.
Of the 18 variants screened, an intronic variant in CYB5R3, I1M?6T (rs8190370), was significantly more common in breast cancer cases compared with controls, and this was attributable to a significantly higher allele frequency in AfrAm cases compared with AfrAm controls. When stratified by smoking, I1M?6T was more strongly associated with breast cancer, particularly in AfrAm women where the allele was most prevalent. When we further analyzed for an interaction between the I1M?6T allele and smoking, the p values were not significant for an interaction on the multiplicative scale. However, given the relatively low allele frequencies overall, the study was underpowered to detect such an interaction.
In the control subjects in this CBCS survey, I1M?6C[T was observed with an MAF that was almost 90-fold higher in AfrAm versus Cauc women. This variant was previously observed in the heterozygous state in 1 of 69 livers (unpublished data from Sacco and Trepanier [35] ), and 2 of 70 breast samples [36] ; all samples were from AfrAm subjects, with b5R immunoreactive protein expression below the 95 % CI for each tissue. The reference C allele is conserved among mammals, and the T variant is predicted to change the splice site at the first intron-exon splice junction of CYB5R3, leading to a truncated transcript. The CYB5R3 I1M?6C[T variant may therefore lead to impaired b5R expression, and this polymorphism merits further functional characterization.
The risk of breast cancer in African American versus Caucasian women has been the subject of a number of studies, most of which have focused on differences in clinical presentation, tumor behavior, and dietary and hormonal exposures [50, 51] . As for interactions between smoking and race, a 1992 study found an association between smoking and breast cancer in white women, but not black women [52] . In the CBCS population used in the present study, smoking was previously found to be a more significant risk factor for breast cancer in AfrAm than Cauc women, based on both duration of active smoking and time since smoking cessation [53, 54] . This relationship was found to be stronger when considering multiple polymorphisms in nucleotide excision repair (NER) genes [54] , which mediate repair of smoking-induced DNA adducts. These studies, together with our data, suggest that the higher risk associated with smoking among AfrAm women may be partly due to genetic variation in pathways that mediate both the detoxification of arylamine and heterocyclic amine tobacco carcinogens and the repair of resulting DNA adducts.
Overall, CYB5A and CYB5R3 polymorphisms were fairly uncommon, with MAF values B0.15 for most variants. This may reflect evolutionary pressure to conserve the function of this pathway, which has an important endogenous role in maintaining hemoglobin in its functional, reduced state [45] [46] [47] . However, several variants were more prevalent in AfrAm women compared with Cauc women. In addition to I1M?6T, the CYB5R3 promoter SNP -251G[T was more than 140-fold more prevalent in AfrAm women, with an MAF (*0.070) that was similar to that reported for native African populations (browser. 1000genomes.org). We previously observed this variant in a heterozygous liver with outlier low b5R expression and hydroxylamine reduction activity (Table 3 ). This SNP is predicted to eliminate VDR/CAR/PXR binding sites, and functional analysis of this SNP using a luciferase reported assay showed a 58 % decrease in expression compared with the wild-type promoter (data not shown).
A third CYB5R3 variant, I8-1676T[C, which was found with [100-fold higher allele frequency in AfrAm women, is within a binding site for RAD21, which could affect DNA double-strand break repair. A final CYB5R3 variant, *392G[C, was found with [30-fold higher frequency in AfrAm women. This variant was previously observed in haplotype configuration in eight breast samples, all from AfrAm women. [36] Although it was not predicted by UTRscan to affect miRNA binding, this 3 0 UTR variant merits functional characterization because of its relatively high prevalence.
Two CYB5A variants also had significantly higher allele frequencies in AfrAm women. One coding SNP, 13T[G (Ser5Ala), was exclusively found in AfrAm subjects, albeit at a very low frequency. This variant was also reported with low frequency in native Africans (MAF 0.020) and was absent in European subjects in the 1000 Genomes Project (browser.1000genomes.org). Another CYB5A variant, I2-992C[T, was observed with [20-fold higher allele frequency in AfrAm women (MAF 0.169); this frequency is intermediate between those reported for African (0.201) and European (0.007) populations (browser.1000genomes. org). I2-992C[T was predicted to be within a binding site for NF-jB, which could affect gene expression [48, 49] .
There are several limitations to this study. Because of low allele frequencies, some of the estimates were imprecise and required that the smoking data be categorized as ever or never smokers. This did not allow consideration of age at smoking initiation, cigarette dosage and duration, or exposure to passive smoke [54, 55] . Our findings should be confirmed in a larger AfrAm population to allow inclusion of more detailed smoking categories. In addition, samples were not fully re-sequenced, so other potentially novel polymorphisms or haplotype associations within CYB5A and CYB5R3 were not evaluated. Finally, we have previously found substantial individual variability in b5 and b5R protein expression, as well as 4-ABP hydroxylamine reduction activities in human breast, which could not be attributed to genetic polymorphisms alone [36] . This suggests that there may be tissue-specific, environmentally induced, or epigenetic regulation of this pathway that may also influence breast detoxification of carcinogenic arylhydroxylamines.
This possibility deserves further study in breast tissues from women with and without breast cancer.
In summary, we found that the CYB5R3 variant I1M?6C[T was significantly overrepresented in women with breast cancer, in particular AfrAm women. Further, there was a suggestion of an interaction of this variant and smoking among AfrAm women. This intronic variant is predicted to cause aberrant splicing of the CYB5R3 transcript, which may lead to decreased b5R expression and impaired detoxification of carcinogenic arylhydroxylamine metabolites. The CYB5R3 I1M?6C[T variant should be considered in the molecular epidemiology studies of breast cancer risk in AfrAms. In addition, this and other variants in CYB5A and CYB5R3 that are overrepresented in AfrAm subjects should be considered in etiologic studies of prostate, bladder, and colon cancers, which are also associated with exposure to arylamine and heterocyclic amine carcinogens [56] [57] [58] .
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